Updated to include the newest drugs and those currently in development, Cancer Chemotherapy and Biotherapy, Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations.
This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised.A companion website includes the fully searchable text and an image bank.
Contents
Section 1: BASIC PRINCIPLES OF CANCER TREATMENT
- 1: Clinical Strategies for Cancer Treatment: The Role of Drugs
- 2: Target Identification and Drug Discovery
- 3: Clinical Drug Development and Approval for Marketing
- 4: Principles of Pharmacokinetics
- 5: Special Aspects of Brain Tumor Chemotherapy
- 6: Pharmacogenetics
- 7: Barriers to Drug Delivery
- 8: Antifolates
- 9: Fluoro-pyrimidines
- 10: Cytidine Analogues
- 11: Purine Analogues
- 12: Hydroxyurea
- 13: Antimitotic Drugs
- 14: Alkylating Agents (Including Methylating Agents)
- 15: Platinum Analogues
- 16: Antitumor Antibiotics (Including Bleomycin)
- 17: Topoisomerase I Inhibitors
- 18: Topoisomerase II Inhibitors: Anthracyclines
- 19: Topoisomerase II Inhibitors: Etoposide, Teniposide
- 20: L-Asparaginase
- 21: Proteosome Inhibitors
- 22: HDAC Inhibitors
- 23: Differentiating Agents (Retinoids)
- 24: Arsenic Trioxide
- 25: Monoclonal Antibodies: Discovery & Development
- 26: Anti-angiogenic Agents (Including MonAB)
- 27: Anti-EGFR Therapies (Including MonAB)
- 28: Anti-her 2 Therapies
- 29: Intracellular Signal Inhibitors (bcr-abl)
- 30: Signal Transduction Inhibitors in Development
- 31: Inhibitors of the PI3k Pathway & Mitotic Kinase
- 32: Interferon and Cytokines
- 33: Vaccines
- 34: Adoptive Cellular Therapies
- 35: Immuno-modulatory Drugs (IMIDS, Anti-CTLA4)
- 36: Hormonal Therapy of Breast Cancer
- 37: GNRH Agonists and Anti-Androgens
- 38: Pain Management in Cancer Patients
- 39: Colony Stimulating Factors
- 40: Anti-nausea Medications
- 41: Bone Loss Modulators
- 42: Intravenous Access and Catheter Management
- 43: Monitoring for Late Side Effects of Chemotherapy
Product Details
- Hardcover: 848 pages
- Publisher: Lippincott Williams & Wilkins; Fifth edition (December 31, 2010)
- Language: English
- ISBN-10: 1605474312
- ISBN-13: 978-1605474311
- Product Dimensions: 11.1 x 8.7 x 1.5 inches